Minimal residual disease (MRD) assessment of hematopoietic neoplasia below 10⁻⁴ requires more leukocytes than is usually attainable by post‐lysis preparation. However, not all laboratories are resourced for consensus Euroflow pre‐lysis methodology. Our study aim was to validate a modified pre‐lysis protocol against our standard post‐lysis method for MRD detection of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and B‐non Hodgkin lymphoma (B‐NHL), to meet demand for deeper MRD assessment by flow cytometry.

中文翻译：

---

验证改进的预裂解样品制备技术，用于多发性骨髓瘤、慢性淋巴细胞白血病和 B 非霍奇金淋巴瘤的流式细胞术微小残留疾病评估。

对低于 10 ^-4的造血瘤形成的微小残留病 (MRD) 评估需要比通常通过裂解后准备获得的更多的白细胞。然而，并非所有实验室都具备一致的 Euroflow 预裂解方法的资源。我们的研究目的是针对我们用于多发性骨髓瘤 (MM)、慢性淋巴细胞白血病 (CLL) 和 B-非霍奇金淋巴瘤 (B-NHL) 的 MRD 检测的标准裂解后方法验证改进的预裂解方案，以满足需要通过流式细胞术进行更深入的 MRD 评估。